Growth & profitability
- Revenue has declined 48.4% per year over the past 5 years.
- Operating margin has contracted, at -102380.2% in the latest year.
CELZ Financials CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6000 | -$6M | 63.4% | -102380.2% | — | — | $7M |
| 2024 | $11000 | -$5M | 60.0% | -52216.9% | — | — | $6M |
| 2023 | $9000 | -$5M | 60.0% | -62445.9% | — | — | $3M |
| 2022 | $88600 | -$10M | 67.8% | -11562.5% | — | — | $8M |
| 2021 | $87754 | $19M | 45.4% | -3562.2% | — | — | $11M |
| 2020 | $164500 | -$36M | 69.2% | -677.7% | — | — | $98012 |
| 2019 | $165500 | -$8M | 72.5% | -682.9% | — | — | $88648 |
| 2018 | $124400 | -$14M | 43.4% | -895.7% | — | — | $304056 |
| 2017 | $4800 | -$3M | -66.7% | -24537.6% | — | $493250 | $13697 |
| 2016 | $0 | -$766072 | — | — | — | — | — |
| 2015 | $0 | -$30761 | — | — | — | — | — |
| 2014 | $0 | -$28012 | — | — | — | — | — |
| 2013 | $0 | -$27282 | — | — | — | — | — |
| 2012 | $0 | -$25585 | — | — | — | — | — |
| 2011 | $0 | -$24055 | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$1M | — | — | — | — | $6M |
| Dec '25 | $3000 | -$2M | 66.9% | -64859.4% | — | — | $7M |
| Sep '25 | $0 | -$1M | — | — | — | — | $5M |
| Jun '25 | $0 | -$1M | — | — | — | — | $7M |
| Mar '25 | $3000 | -$2M | 60.0% | -55349.3% | — | — | $8M |
| Dec '24 | $3000 | -$2M | 60.0% | -62857.8% | — | — | $6M |
| Sep '24 | $0 | -$1M | — | — | — | — | $6M |
| Jun '24 | $8000 | -$2M | 60.0% | -20316.3% | — | — | $7M |
| Mar '24 | $0 | -$1M | — | — | — | — | $9M |
| Dec '23 | $3000 | -$2M | 60.0% | -59061.3% | — | — | $3M |
| Sep '23 | $6000 | -$1M | 60.0% | -25719.8% | — | — | $5M |
| Jun '23 | $0 | -$1M | — | — | — | — | $4M |
| Mar '23 | $0 | -$1M | — | — | — | — | $10M |
| Dec '22 | $18600 | -$6M | 69.4% | -33752.3% | — | — | $8M |
| Sep '22 | $55000 | -$982339 | 70.9% | -1855.3% | — | — | $17M |
| Jun '22 | $0 | -$2M | — | — | — | — | $23M |
| Mar '22 | $15000 | -$1M | 54.7% | -7699.1% | — | — | $9M |
| Dec '21 | $67754 | -$4M | 41.8% | -2173.6% | — | — | $11M |
| Sep '21 | $10000 | -$2M | 60.0% | -8334.4% | — | $5M | $2M |
| Jun '21 | $10000 | -$3M | 55.0% | -5158.4% | — | $342452 | — |
Valuation over time
How the market has priced CELZ against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 21.5× (Mar '23) to 942.7× (Jun '26).
P/S
Frequently asked questions
Is CELZ growing its revenue and profit?
Over the past 5 years, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s revenue has declined 48.4% per year. These are computed facts, not advice.
How much debt does CELZ have?
As of FY2025, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reported — of total debt against $7M of cash.
What is CELZ's profit margin?
In FY2025, gross margin was 63.4%, operating margin -102380.2%, and net margin -99916.8%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.